Fluoroestradiol

Summary

Fluoroestradiol (CHEMBL1627367) is an approved small molecule; indicated across 4 conditions including breast carcinoma and invasive lobular breast carcinoma.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 4 conditions
• Clinical trials: 1
• Chemistry: 290.4 Da · C18H23FO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1627367
Name	Fluoroestradiol
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	10401972
Molecular formula	C18H23FO2
Molecular weight	290.4
InChIKey	KDLLNMRYZGUVMA-ZXXIGWHRSA-N

SMILES: C[C@]12CC[C@H]3[C@H]([C@@H]1C[C@H]([C@@H]2O)F)CCC4=C3C=CC(=C4)O

IUPAC name: (8R,9S,13S,14S,16R,17R)-16-fluoro-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol

Also known as: 16.alpha.-fluoroestradiol, Fluoroestradiol, 16.alpha.-, Fluoroestradiol, FLUOROESTRADIOL

Parent form; salt/anhydrous children: CHEMBL4594261

Patent coverage: 31 distinct patent families (57 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 55 (96%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
breast carcinoma	2	MONDO:0004989	EFO:0000305
invasive lobular breast carcinoma	2	MONDO:0005051	EFO:0000553
uterine cancer	2	MONDO:0002715	MONDO:0002715
breast neoplasm	2	MONDO:0021100	MONDO:0007254

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03065712	PHASE2	WITHDRAWN	Test - Retest Reproducibility of 18F Fluoroestradiol (FES) PET

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).